aGVHD Clinical Trial
Official title:
Prospective Study of Combined ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT
The purpose of this study is to determine the efficacy and safety of combined ATG (antithymocyte globulin ) regimen for aGVHD(acute graft-versus-host disease ) prophylaxis in matched sibling donor peripheral blood stem cell transplantation (MSD-PBSCT).
Transplantation with G-CSF (Granulocyte colony stimulating factor )mobilized peripheral blood stem cell (PBSCT) has been a stable transplant setting with matched sibling donor transplantation. Unmanipulated haploidentical donor PBSCT (haplo-PBSCT) has been applied in patients with hematologic malignancies. In our previous cohort study, haplo-PBSCT was associated with lower incidence of severe acute GVHD and extensive chronic GVHD compared with matched sibling donor PBSCT (MSD-PBSCT). Haplo-PBSCT has the same GVHD prophylaxis regimen with MSD-PBSCT, except ATG. It suggested the potential advantage of ATG in prophylaxis of GVHD and improvement of long-term quality of life of the transplant recipients, which motivate us to observe the efficacy of combined ATG regimen for GVHD prophylaxis in MSD-PBSCT. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05531266 -
Umbilical Cord Mesenchymal Stem Cells as First-line Treatment for Patients With Acute Graft Versus Host Disease
|
N/A | |
Recruiting |
NCT02848105 -
Valproic Acid With Methylprenisonlone for the Treatment of Acute GVHD
|
Phase 2 | |
Completed |
NCT03763318 -
A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD
|
Phase 1/Phase 2 | |
Completed |
NCT04397367 -
Low Dose Ruxolitinib in Combination With Methylprednisolone
|
Phase 1/Phase 2 | |
Recruiting |
NCT05214066 -
Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT
|
Phase 2 | |
Recruiting |
NCT03614143 -
Biomarker Study for Prediction of aGVHD
|
||
Completed |
NCT04061876 -
First Line Therapy for High Risk Acute GVHD
|
Phase 2 | |
Recruiting |
NCT05263999 -
A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
|
Phase 3 |